非小细胞肺癌抗PD-1治疗后发生的肺结核 - Suppr

Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer.

作者信息

Jensen Kristian Hastoft, Persson Gitte, Bondgaard Anna-Louise, Pøhl Mette

机构信息

a Department of Oncology , Rigshospitalet Copenhagen University Hospital , Copenhagen , Denmark.

b Department of Pathology , Rigshospitalet Copenhagen University Hospital , Copenhagen , Denmark.

出版信息

Acta Oncol. 2018 Aug;57(8):1127-1128. doi: 10.1080/0284186X.2018.1433877. Epub 2018 Jan 31.

DOI:10.1080/0284186X.2018.1433877

PMID:29384034

Abstract

摘要

相似文献

Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer.

Acta Oncol. 2018 Aug;57(8):1127-1128. doi: 10.1080/0284186X.2018.1433877. Epub 2018 Jan 31.

Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.

Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618801167. doi: 10.1177/1753466618801167.

Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient.

Ann Oncol. 2018 Jan 1;29(1):286-287. doi: 10.1093/annonc/mdx548.

Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient.

Oncol Res Treat. 2017;40(10):621-622. doi: 10.1159/000477968. Epub 2017 Sep 19.

Ann Oncol. 2017 Jun 1;28(6):1405-1406. doi: 10.1093/annonc/mdx126.

Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents.

J Infect Chemother. 2019 Jan;25(1):54-58. doi: 10.1016/j.jiac.2018.06.016. Epub 2018 Jul 25.

Severe pulmonary infections complicating nivolumab treatment for lung cancer: a report of two cases.

Acta Clin Belg. 2020 Aug;75(4):308-310. doi: 10.1080/17843286.2019.1629078. Epub 2019 Jun 9.

New onset of psoriasis during nivolumab treatment for lung cancer.

J Dermatol. 2018 Mar;45(3):e55-e56. doi: 10.1111/1346-8138.14167. Epub 2017 Dec 4.

Extensive-Stage Small-Cell Lung Cancer With Sustained Complete Response to Single-Agent Nivolumab and Immune-Related Dermatitis.

Clin Lung Cancer. 2020 Jan;21(1):e6-e9. doi: 10.1016/j.cllc.2019.09.005. Epub 2019 Sep 26.

Late Gastrointestinal Toxicity During Nivolumab Therapy in Non-Small Cell Lung Cancer: A Rare Case of Inflammatory Bowel Disease.

J Thorac Oncol. 2018 Aug;13(8):e152-e153. doi: 10.1016/j.jtho.2018.03.022.

引用本文的文献

Simultaneous Anti-Tuberculosis and Anti-Tumor Treatment with Immune Checkpoint Inhibitors for Co-Existent Pulmonary Tuberculosis and Advanced Lung Cancer.

Infect Drug Resist. 2025 Jan 6;18:107-112. doi: 10.2147/IDR.S497006. eCollection 2025.

A narrative review of the controversy on the risk of mycobacterial infections with immune checkpoint inhibitor use: does Goldilocks have the answer?

J Thorac Dis. 2024 Feb 29;16(2):1601-1624. doi: 10.21037/jtd-23-1395. Epub 2024 Feb 27.

Pulmonary Tuberculosis Following Immune Checkpoint Inhibitor Treatment for Recurrent Maxillary Squamous Cell Carcinoma.

Cureus. 2024 Jan 29;16(1):e53203. doi: 10.7759/cureus.53203. eCollection 2024 Jan.

Increased Tuberculosis Incidence Due to Immunotherapy Based on PD-1 and PD-L1 Blockade: A Systematic Review and Meta-Analysis.

Front Immunol. 2022 May 19;13:727220. doi: 10.3389/fimmu.2022.727220. eCollection 2022.

The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with infection.

Transl Lung Cancer Res. 2021 Oct;10(10):3929-3942. doi: 10.21037/tlcr-21-524.

Tuberculosis reactivation at ileum following immune checkpoint inhibition with pembrolizumab for metastatic nasopharyngeal carcinoma: a case report.

BMC Infect Dis. 2021 Nov 10;21(1):1148. doi: 10.1186/s12879-021-06845-7.

Exacerbation of nontuberculous mycobacterial pulmonary disease in a patient with advanced non-small-cell lung cancer during treatment with PD-1 inhibitor and chemotherapy.

Respir Med Case Rep. 2021 Oct 21;34:101529. doi: 10.1016/j.rmcr.2021.101529. eCollection 2021.

Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy.

Thorax. 2022 Mar;77(3):304-311. doi: 10.1136/thoraxjnl-2021-217260. Epub 2021 Oct 4.

Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study.

J Immunother Cancer. 2021 Sep;9(9). doi: 10.1136/jitc-2021-002960.

Immune Checkpoint Inhibitors in Special Populations.

Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211036526. doi: 10.1177/15330338211036526.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献